124I-DPA-713(巨噬细胞相关炎症PET示踪剂)的生物分布与辐射剂量学
6名健康成人(平均年龄40±19岁)静脉注射124I-DPA-713后行全身PET/CT,平均给药活度70.5±5.1 MBq、质量469±34 ng。示踪剂4小时从肺部快速清除,主要经肝脏排泄并进入胃肠道;平均有效剂量0.459±0.127 mSv/MBq,肝脏为剂量限制器官(0.924±0.501 mGy/MBq)。6名受试者均无不良反应或可临床检测的药理效应。
要点
- 124I-DPA-713在健康成人中安全耐受,6名受试者无不良反应或可检测药理效应。
- 平均有效剂量0.459±0.127 mSv/MBq,肝脏为剂量限制器官(0.924±0.501 mGy/MBq)。
- 示踪剂4小时从肺部快速清除,主要经肝脏排泄并定位至胃肠道。
核心结论
- 124I-DPA-713从肺部快速清除,主要经肝脏排泄,在健康成人中安全且耐受良好。
研究设计与样本
- 健康受试者(18-65岁)静脉注射124I-DPA-713后行全身PET/CT,于注射后4、24、48小时或24、48、72小时显像。
- 共3名男性与3名女性成人完成显像,平均年龄40±19岁。
- 平均给药活度70.5±5.1 MBq(范围62.4-78.1 MBq),平均给药质量469±34 ng(范围416-520 ng)。
- 受试者进行TSPO rs6971基因分型,并测定124I-DPA-713的血浆蛋白结合率。
主要发现
- 6名受试者均无不良反应或可临床检测的药理效应,生命体征、实验室值和心电图未见变化。
- 124I-DPA-713在注射后4小时从肺部快速清除,经肝脏排泄并定位至胃肠道。
- 6名受试者平均有效剂量为0.459±0.127 mSv/MBq,肝脏为剂量限制器官(0.924±0.501 mGy/MBq)。
- 注射后30和60分钟,血液中游离放射性示踪剂百分比约为30%。
关键数值与推荐
- 6名受试者平均有效剂量0.459±0.127 mSv/MBq,肝脏吸收剂量0.924±0.501 mGy/MBq。
- 注射后30和60分钟血液游离放射性示踪剂百分比约为30%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Whole-body PET/CT was performed using 124I-DPA-713, a radioligand for the 18-kDa translocator protein (TSPO), to determine biodistribution and radiation dosimetry. Methods: Healthy subjects aged 18-65 y underwent whole-body PET/CT either at 4, 24, and 48 h or at 24, 48, and 72 h after intravenous injection of 124I-DPA-713. Time-activity curves were generated and used to calculate organ time-integrated activity coefficients for each subject. The resulting time-integrated activity coefficients provided input data for calculation of organ absorbed doses and effective dose for each subject using OLINDA. Subjects were genotyped for the TSPO polymorphism rs6971, and plasma protein binding of 124I-DPA-713 was measured. Results: Three male and 3 female adults with a mean age of 40 ± 19 y were imaged. The mean administered activity and mass were 70.5 ± 5.1 MBq (range, 62.4-78.1 MBq) and 469 ± 34 ng (range, 416-520 ng), respectively. There were no adverse or clinically detectable pharmacologic effects in any of the 6 subjects. No changes in vital signs, laboratory values, or electrocardiograms were observed. 124I-DPA-713 cleared rapidly (4 h after injection) from the lungs, with hepatic elimination and localization to the gastrointestinal tract. The mean effective dose over the 6 subjects was 0.459 ± 0.127 mSv/MBq, with the liver being the dose-limiting organ (0.924 ± 0.501 mGy/MBq). The percentage of free radiotracer in blood was approximately 30% at 30 and 60 min after injection. Conclusion:124I-DPA-713 clears rapidly from the lungs, with predominantly hepatic elimination, and is safe and well tolerated in healthy adults.
引用
- Foss CA, Plyku D, Ordonez AA, et al. Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation. J Nucl Med. 2018. PMID: 29700124. doi:10.2967/jnumed.117.207431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。